FTC Reaches Settlement with Caremark in Antitrust Case
The FTC has secured a major settlement with Caremark, resolving an antitrust case against the drug middleman
The Federal Trade Commission has reached a settlement with Caremark, resolving an antitrust case against the company, as announced on the Federal Trade Commission website. This settlement is part of a broader effort to crack down on deceptive practices, similar to the FTC Cracks Down on Deceptive Claims in other industries. The case alleged that Caremark, a pharmacy benefit manager, artificially inflated the list price of insulin drugs using anticompetitive and unfair rebating practices. This development comes as other companies, such as Paramount, face their own antitrust challenges, including a merger with Warner Bros. that is being closely watched, with more information available on the Paramount-Warner Bros Merger Faces Multiple Antitrust Challenges. Meanwhile, a shareholder lawsuit against Paramount, reported by latimes.com, accuses the company's leaders of corruption.
Cross-reference independently — do not take our word for it.
Disclosure: NewsAnarchist uses AI-assisted reporting with web search. Always verify primary sources linked above.
This article is produced by NewsAnarchist's AI reporting system, not a human staff reporter. It's built from the primary source cited above (a regulator's enforcement action (SEC, FTC, DOJ), a company's own SEC filing, a court record, or the wire/trade-press reporting linked in the body) and reports what that source states, attributed to it — it is not a recommendation about any company's stock or products, and does not verify a company's disputed denial beyond what the record shows. Part of our Corporate Watchdog hub. Found an error? Tell us.